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Summary Behc¸et’s disease (BD) is a multisystemic disease of unknown etiopatho-
genesis with various clinical features including manifestations from central nervous
system involvement. We report the case of a patient presented with a 20-year history
of BD and a 10-year history of epileptic seizures refractory to various antiepileptic
drugs. Under systemic treatment with interferon-a 2a (IFN-a) a complete remission of
the cutaneous manifestations and a seizure-free state were achieved. The impressive
therapeutic response of both the seizures and the non-neurological manifestations to
IFN-a was also observed upon re-administration of this cytokine subsequent to a
severe BD relapse. In view of this response and the lack of any other obvious etiology
of the seizures in our patient, it seems reasonable to consider them as being the sole
manifestation of neuro-BD. The patient is presently completing a 40-month seizure-
free follow-up, despite withdrawal of all antiepileptic drugs for the last 35 months.
Further studies on large numbers of patients are now warranted to define the
therapeutic efficacy and safety of IFN-a in neuro-BD and particularly in neuro-BD-
related epileptic seizures.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
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genital ulcerations, ocular manifestations and by
involvement of the gastrointestinal, cardiovascular,
pulmonary, skeletal and central nervous systems
(CNS).1 In this paper, we report a patient with
epileptic seizures as the sole manifestation of neu-
rological involvement (neuro-BD), which were suc-
cessfully controlled with interferon-alpha (IFN-a).. Published by Elsevier Ltd. All rights reserved.
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In January 2001, a Greek 47-year-old man with a 20-
year history of painful and recurrent oral and skin
lesions was admitted to the Department of Derma-
tology, at the University of Patras Medical Center.
According to the patient, no definite diagnosis had
been made with regard to his oral and skin lesions by
his hometown dermatologists, who had treated him
over a period of 20 years with steroids with limited
success.
Additionally, the patient had a 10-year history of
generalized tonic—clonic seizures occurring during
sleep (6—8 month1) and complex partial type sei-
zures occurring during daytime (4—5 month1),
that were characterized by impairment of con-
sciousness, an unpleasant feeling arising from his
stomach followed by involuntary swallowing move-
ments and by optic hallucinations. He consulted
several neurologists, who described an unremark-
able neurological examination. In the electroence-
phalogram (EEG) they found paroxysmal activity
consisting of short or long series of slow activity
at 3—5 Hz intermixed with isolated sharp and slow
wave complexes independently occurring over the
left and less frequently over the right temporal
area. Since brain MRI disclosed no lesions and the
cerebrospinal fluid analysis and the routinely per-
formed laboratory investigations showed no
abnormalities, the patient’s epilepsy was consid-
ered by his neurologists to be cryptogenic. As they
stated, the therapeutic response to sodium valpro-
ate 1500 mg/day and to lamotrigine (200 mg/day),
which was additionally given, was disappointing.
Over the next 10 years, the patient reportedly
switched to oxcarbazepine (1200 mg/day) and later
to topiramate (300 mg/day) and levetiracetam
(3000 mg/day) without any beneficial effect on
the frequency of his seizures. However, as we were
informed by his neurologists, the plasma levels of
the administered antiepileptic drugs had never
been monitored.
On the first admission of the patient to our Insti-
tution, physical examination revealed aphthous
lesions in the oral mucosa, erythema nodosum on
the extensor surface of both lower extremities,
pseudofolliculitis lesions on the trunk and a positive
pathergy (needle reaction) test. Since the patient
fulfilled the criteria of the International Study
Group for BD, the diagnosis of BD was established.2
Apart from an increase of the erythrocyte sedimen-
tation rate and of g-glutamyl transferase serum
levels, the results of all biochemical, haematologi-
cal, serological, X-ray, ultrasound, ophthalmologic,
cardiologic and clinical neurological examinations
were either negative or within normal limits. Inparticular, the autoimmune screening including
antinuclear, anti-DNA, anti-single and double
stranded DNA, anti-SM, anti-Ro, anti-La and lupus
anticoagulant antibodies, IgG anti-cardiolipin, C3 &
C4 components of the complement, rheumatoid
factor, ASMA, AMA, APA, p-ANCA, c-ANCA, immuno-
globulins, cryoagglutinins was unremarkable. Upon
his admission and despite continuation of treatment
with topiramate (300 mg/day) and levetiracetam
(3000 mg/day), the patient suffered from frequent
epileptic seizures.
For the therapeutic management of BD human
recombinant IFN-a (Roferon; Roche Hellas, Athens,
Greece) was subcutaneously administered to the
patient at a dose of 6  106 IU per day, three times
per week. Symptoms of influenza-like syndrome
could be prevented by oral paracetamol given to
the patient 30 min prior to interferon administra-
tion. Apart from a transient depression of white-cell
counts, no significant alterations of laboratory vari-
ables could be detected, as compared to the pre-
treatment phase. Already after 2 weeks of
treatment oral aphthae completely disappeared,
whereas a complete remission of erythema nodosum
and pseudofolliculitis was observed by the end of
the fourth and the fifth week, respectively. Addi-
tionally, under interferon therapy and the continu-
ing antiepileptic medication, a progressive decrease
in the frequency of the patient’s seizures was
observed and for the first time a seizure-free state
was achieved 5 months after onset of IFN-a therapy.
In September 2001, the patient decided to dis-
continue the interferon administration but kept on
taking his antiepileptic medication. He remained
thereafter free of any cutaneous lesions and sei-
zures until June 2004 when he was readmitted due
to a massive relapse characterized by the occur-
rence of multiple aphthous lesions in the oral cavity,
the cecum and the sigmoid, erythema nodosum on
the lower extremities, pseudofolliculitis on the
trunk, positive pathergy test and epileptic seizures.
IFN-a administration (6  106 IU per day, three
times per week) was then restarted and led to a
complete remission of the disease within 9 weeks. In
view of the favourable response of his severe intest-
inal involvement and seizures to IFN-a, the patient
received from June 2004 until August 2007 the same
dosage of IFN-a. Since September 2007, he receives
3  106 IU IFN-a two times per week, whereas his
antiepileptic medication has been discontinued
since January 2005. The patient is presently com-
pleting a 35-month antiepileptic-free follow-up and
reveals no seizures or any non-neurological mani-
festations of BD, whereas his EEG pattern has
returned to normal. IFN-a is well tolerated and no
signs of depression have been found.
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Although the etiopathogenesis of BD remains to be
elucidated, it is generally accepted that a severe
vasculitis involving arteries and veins of all sizes is
the cardinal pathological substrate of the affected
tissues and organs in this disorder.3 Viral and bac-
terial antigens are thought to be implicated in the
development and maintenance of this vasculitis in
genetically predisposed individuals.
Neurological involvement in BD varies from 2.5 to
49% of cases and represents one of the most severe
BD manifestations. Two distinct patterns of CNS
involvement have been recognized, parenchymal
and non-parenchymal or neuro-vascular.1,4 Data
on the occurrence of epileptic seizures as evidence
of parenchymal CNS involvement in BD are very
sparse. The reported frequency of the seizures
greatly varies (0—27%), probably depending on eth-
nicity and environmental factors.4,5 Epileptic sei-
zures may occur during either the exacerbations or
the chronic course of BD as simple or complex partial
seizures, myoclonic jerks and generalized tonic—
clonic seizures.5—7 To our knowledge, there is only
one clearly documented report of neuro-BD present-
ing with seizures,6 followed later by other CNS
manifestations.
The case presented here could be regarded as
rather atypical for neuro-BD and a mere casual co-
existence of epilepsy and BD should be taken into
consideration. However, this possibility seems very
unlikely in view of: (1) the absence of any obvious
etiology despite vigorous investigations over a 10-
year period and (2) the impressive therapeutic
response of both, the seizures and the non-neuro-
logical manifestations of BD in our patient not only
to the initial IFN-a course of treatment but also to
its re-administration (subsequent to BD relapse) and
the 40-month seizure-free follow-up, despite with-
drawal of all antiepileptic drugs for the last 35
months. It seems reasonable, therefore, to consider
the epileptic seizures of our patient as being the
sole manifestation of CNS involvement in BD (neuro-
BD). In the majority of cases with neuro-BD-related
epileptic seizures, EEG shows non-specific slow
activity and only rarely distinct focal abnormalities
are seen. Brain MRI often discloses single or scat-
tered focal lesions suggestive of CNS vasculitis.1,6,7
The EEG findings in our case confirmed the diagnosis
of epilepsy and implied the presence of a focal
temporal dysfunction. In view of the low sensitivity
of MRI in detecting cerebral dysfunction,8 the
absence of structural lesions on brain MRI, as in
our case, does not exclude the diagnosis of neuro-
BD. In a retrospective study Aykutlu et al.5 reported
that treatment with conventional antiepileptics wascapable of controlling the seizures in most evalu-
ated patients with neuro-BD. The striking therapeu-
tic failure of first choice antiepileptic drugs
observed in our patient keeps up with the findings
of Aktekin et al.7 in a severe case of neuro-BD, in
which these compounds caused a reduction in the
frequency but not a complete cessation of seizures.
Tsambaos et al.9 were the first to introduce the
systemic application of IFN-a in the treatment of
BD. The impressive therapeutic results observed by
these authors were confirmed in a large number of
subsequent clinical trials. Thus, IFN-a is presently
regarded as a highly effective, safe and well toler-
ated form of therapy for themucocutaneous, articu-
lar and ocular manifestations of BD.10,11 To our
knowledge, the efficacy of this cytokine in the
management of neuro-BD-related epileptic seizures
has never been studied. Nichols et al.12 reported
resolution of generalized tonic—clonic seizures in a
patient with neuro-BD and attributed it to IFN-a
treatment. Nevertheless, the concomitant admin-
istration of colchicine to their patient, a compound
with well-known therapeutic effects on BD, ham-
pered the assessment of the therapeutic efficacy of
IFN-a alone. It is obvious that, due to the sponta-
neous exacerbations and remissions marking the
clinical course of BD, the evaluation of various
therapeutic regimens is difficult. However, the pre-
sented case shows, for the first time, that IFN-a was
capable of completely controlling neuro-BD-related
epileptic seizures. The mechanisms underlying the
therapeutic action of IFN-a on the seizures of our
patient remain unclear. It is possible, however, that
IFN-a, apart from its immunomodulatory action on
the molecular and cellular components of BD-
related vasculitis, may exert a direct effect on
neural tissue.
In the presented case epilepsy was considered as
refractory since our patient had failed to respond to
more than three drugs and experienced more than
3—4 seizures per month.13 One could argue that the
limited therapeutic response of the epilepsy of our
patient may be associated with a possibly limited
bioavailability of the administered antiepileptic
drugs. Unfortunately, for unknown reasons, the
plasma levels of the latter were not determined
during the 10-year treatment of the patient by his
hometown neurologists. Upon his admission to our
Institution the patient has been receiving levetir-
acetam (3000 mg/day) and topiramate (300 mg/
day), the plasma levels of which were not deter-
mined because their monitoring is of limited clinical
value. Furthermore, a clinically relevant interaction
of these antiepileptic agents with IFN-a, which
could have caused alterations of their plasma levels,
is almost impossible for the following reasons:
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no potential to produce clinically relevant phar-
macokinetic drug interactions through inhibition
or induction of liver CYP450 enzymes.14 On the
other hand, it undergoes minimal metabolism
(<2.5%) by CYP450 enzymes which is not altered
by known CYP450 inducers and inhibitors.152. IFN-a is known to be capable of inducing CYP1A,
CYP2C19, CYP2D6 and CYP2E1.16 None of these
enzymes catalyzes the metabolism of Topira-
mate, which is metabolized by CYP3A4. The
latter is induced by its substrate.17 Further stu-
dies on large numbers of patients are now war-
ranted to define the therapeutic efficacy and
safety of IFN-a in neuro-BD and particularly in
neuro-BD-related epileptic seizures.
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